Parkinson's Disease Treatment Market to Witness Substantial Growth USD 7.74 billion, with a Dynamic 6.2% Growth Rate by 2030 | Key Players- Abbvie Inc, Acadia Pharmaceuticals Inc,Apotex Inc

The progressing ecological elements and genetic tendencies have been influential factors in the increasing growth and revenue of the Parkinson's disease treatment industry. Based on drug class analysis, the MAO-inhibitors segment accounted for the highest share. By region, North America spearheaded the market.

𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐀𝐝𝐝𝐫𝐞𝐬𝐬𝐞𝐬:

• The global Parkinson's disease treatment market was valued at USD 4.55 billion in 2021 and is expected to grow to USD 7.74 billion by 2030.
• The market is anticipated to exhibit a CAGR of 6.2% during the forecast period.
• The market is mainly segmented on the basis of drug class, distribution channel, route of administration, patient care setting, and region.
• North America accounted for the largest market share.

𝐆𝐞𝐭 𝐈𝐧𝐬𝐭𝐚𝐧𝐭 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐎𝐮𝐫 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.polarismarketresearch.com/industry-analysis/global-parkinsons-disease-treatment-market/request-for-sample

𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰

Medicines may assist in handling issues with walking, gestures, and trembling. These medications escalate or relieve dopamine. Persons with Parkinson's disease have degraded levels of brain dopamine. However, dopamine cannot be administered instantly as it can penetrate the brain. One may have notable enhancement of indications subsequent to commencing of Parkinson's disease treatment. But as time passes, the advantages of medicines often shrink or become least congruous. One can normally yet regulate the indications well. Levodopa is the most efficacious Parkinson's disease medicine, is an organic chemical that traverses into the brain and is transformed to dopamine.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐨𝐧 𝐂𝐚𝐭𝐞𝐠𝐨𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧

Prominent players are acquiring programs such as mergers & acquisitions and associations for regional augmentation and a considerable market share. Key companies in the Parkinson's disease treatment market are mentioned below:
• Abbvie Inc.
• Acadia Pharmaceuticals Inc.
• Apotex Inc.
• Axovant Gene Therapies Ltd.
• Boehringer Ingelheim GmbH
• Bausch Health Companies Inc.
• Boston Scientific Corp.
• Cipla Inc.
• Daiichi Sankyo Espha Co.
• Ltd.
• Eli Lilly & Co.
• Eisai Co. Ltd.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline Plc

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐍𝐨𝐰 𝐟𝐨𝐫 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: https://www.polarismarketresearch.com/industry-analysis/global-parkinsons-disease-treatment-market/inquire-before-buying

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬

The Parkinson's disease treatment market is expected to surge due to the robust pipeline of contemporary medicines for the condition. For instance, in October 2021, Appello Pharmaceuticals Inc., a diagnostic and remedial firm committed to detecting contemporary premature drug targets for patients with neurological illnesses, commenced phase 1 clinical studies of a Parkinson's disease possibility drug configured at Warren Center for Neuroscience Drug Discovery.

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

• North America (U.S., Canada)
• Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
• Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
• Latin America (Brazil, Mexico, Argentina)
• Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰

Parkinson's Disease Treatment, Drug Class Outlook (Revenue - USD Billion, 2018 - 2030)
• Levodopa/carbidopa
• Dopamine Receptor Agonists
• MAO-Inhibitors
• COMT-inhibitors
• Anticholinergics
• Other Drugs

Parkinson's Disease Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Parkinson's Disease Treatment, Route of Administration Setting Outlook (Revenue - USD Billion, 2018 - 2030)
• Oral
• Subcutaneous
• Transdermal
• Others

Parkinson's Disease Treatment, Patient Care Setting Outlook (Revenue - USD Billion, 2018 - 2030)
• Clinics
• Hospitals

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞: https://www.polarismarketresearch.com/industry-analysis/global-parkinsons-disease-treatment-market

𝐏𝐚𝐫𝐤𝐢𝐧𝐬𝐨𝐧'𝐬 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬

• COMT-inhibitors are anticipated to grow at the highest CAGR over the forecast period. Levodopa (LD) therapy has been shown to benefit from the addition of COMT inhibitors since they enhance LD bioavailability and prolonged LD elimination in Parkinson's patients. To increase their use and demand, COMT inhibitors must demonstrate their benefits.

• Hospital segment records significant revenue share because therapy and treatments can be delivered on-site. Reducing the necessity for pharmacy visits and increasing the use of hospital settings.

• Asia-Pacific is expected to hold the fastest CAGR over the forecast period. This is expanding due to increased healthcare organizations and Parkinson's disease prevalence. Additionally, the region's growing senior population impacts the market for these disease treatments.

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Refurbished Medical Imaging Equipment Market: https://www.polarismarketresearch.com/industry-analysis/refurbished-medical-imaging-equipment-market

Histology And Cytology Market: https://www.polarismarketresearch.com/industry-analysis/histology-cytology-market

Scar Treatment Market: https://www.polarismarketresearch.com/industry-analysis/scar-treatment-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.